Last updated: 2026-09-16 12:18:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Aquestive Therapeutics, Inc. (AQST) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.93, with a market capitalisation of $612.50M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.93 to $7.55. This page covers its latest market performance, valuation, price trends and company information.
$612.50M | |
$4.88 | |
$20.70 | |
$0.62 | |
$4.81 | |
10.00 | |
2.77M | |
-- | |
$7.55 | |
$2.93 | |
-- | |
-- |
Aquestive Therapeutics, Inc. (AQST) is trading at $4.93 in pre-market trading as of 2026-09-16 11:46:00, up 2.39% ($0.12) from the previous close of $4.81
Pre-market trading shows how investors are pricing AQST before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Aquestive Therapeutics, Inc. (AQST) moved from $5.34 to $4.93, representing a decline of 7.77% ($0.42).
The stock traded between $4.66 and $5.49 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.50 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 43.2%
AQST is currently trading at $4.93, placing it 43.2% of the way from its 52-week low of $2.93 to its 52-week high of $7.55. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 147 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aquestive Therapeutics, Inc. (AQST) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.